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Abstract 
 
Objective 
The aim of this literature review is to identify the role of probiotics in the 
management of enteral tube feeding (ETF) diarrhoea in critically ill patients. 
 
Background 
Diarrhoea is a common gastrointestinal problem seen in ETF patients. The 
incidence of diarrhoea in tube-fed patients varies from 2% to 68% across all patients. 
Despite extensive investigation, the pathogenesis surrounding ETF diarrhoea remains 
unclear. Evidence to support probiotics to manage ETF diarrhoea in critically ill patients 
remains sparse. 
 
Method 
Literature on ETF diarrhoea and probiotics in critically ill, adult patients was 
reviewed from 1980 to 2010. The Cochrane Library, Pubmed, Science Direct, Medline 
and the Cumulative Index of Nursing and Allied Health Literature (CINAHL) electronic 
databases were searched using specific inclusion/exclusion criteria. Key search terms 
used were: enteral nutrition, diarrhoea, critical illness, probiotics, probiotic species and 
randomised clinical control trial (RCT). 
 
Results 
Four RCT papers were identified with two reporting full studies, one reporting a 
pilot RCT and one conference abstract reporting an RCT pilot study. A trend towards a 
reduction in diarrhoea incidence was observed in the probiotic groups. However, 
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mortality associated with probiotic use in some severely and critically ill patients must 
caution the clinician against its use. 
 
Conclusion 
Evidence to support probiotic use in the management of ETF diarrhoea in 
critically ill patients remains unclear. This paper argues that probiotics should not be 
administered to critically ill patients until further research has been conducted to 
examine the causal relationship between probiotics and mortality, irrespective of the 
patient’s disease state or projected prophylactic benefit of probiotic administration. 
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INTRODUCTION 
 
Nutritional support is widely accepted as standard care for critically ill patients 
(Jolliet et al., 1999; Casse et al., 2000; Heyland, 2000).
 
Approximately 60% of critically 
ill patients receive enteral nutrition during their intensive care unit (ICU) stay (Lee and 
Auyeung, 2003). A common gastrointestinal problem in enterally tube fed (ETF) 
patients is diarrhoea (Whelan et al., 2001). Electrolyte imbalance, dehydration, perianal 
skin breakdown, wound contamination, alterations in intestinal micro flora, 
psychological embarrassment, sleep disturbances and increased health care costs may be 
complications associated with ETF diarrhoea. Diarrhoea management strategies and 
ETF practices vary widely between ICUs. This is evidenced by the disagreement seen in 
diarrhoea management strategies including the administration of probiotics in some 
critical care environments (Cole et al., 1998; Barbut and Meynard, 2000; Whelan et al., 
2001; Whelan et al., 2003; Weisen et al., 2006). 
 
Background 
Enteral Tube Feeding 
The optimal time to start nutritional support in critical illness remains unclear. It 
is widely accepted to commence ETF in the ICU as early as possible as ETF is 
purported to preserve the gut’s immunological barrier, reduce bacterial translocation, 
reduce rates of sepsis and multi organ failure and improve wound healing (Kennedy, 
1997; Marshall and West, 2004; Davies and Bellomo, 2004; Lopez-Herce et al., 2008). 
However, ETF is not without complications including diarrhoea, abdominal distension, 
pulmonary aspiration, hyperglycaemia, electrolyte derangement, dehydration and 
secondary infections (Pancorbo-Hidalgo et al., 2001; Williams and Leslie, 2004; Lopez-
 7 
Herce et al., 2008). It is not uncommon for ETF to be delayed or ceased for these 
reasons (Adam and Batson, 1997; Heyland et al., 2003). 
 
 
Diarrhoea Epidemiology 
The incidence of diarrhoea in ETF patients is suggested to vary between 2% to 
68% (Bowling, 1995; Bowling, 1998; Cole et al., 1998; Bengmark, 2002; Whelan et al., 
2001; McNaught et al., 2005; Weisen et al., 2006;). However, the incidence of diarrhoea 
is argued to vary more widely between 2% to 95% in critically ill patients (Cataldi-
Betcher et al., 1983; DeMao et al., 1998). The variability of diarrhoea incidence 
reported in different subsets of hospitalised patients may be related to the 
inconsistencies in diarrhoea definitions and the clinical application of these definitions 
(Whelan et al., 2003; Weisen et al., 2006). Therefore, the prevalence of diarrhoea may 
depend on the definition used (Lebak et al., 2003; Weisen et al., 2006). 
 
Diarrhoea Pathogenesis 
The pathogenesis of diarrhoea in critical illness remains unclear; however, 
diarrhoea is thought to be caused by infectious and non-infectious aetiologies (Weisen 
et al., 2006). The higher incidence of ETF diarrhoea in critical illness may be related to 
(i) microbial contamination of the ETF formula; (ii) altered colonic responses to intra 
gastric feeding; (iii) hypoalbuminaemia; (iv) increased use of antibiotic therapy; and (v) 
medications such as stool softeners, prokinetics and histamine-2 agents (Bowling, 1995; 
Cole et al., 1998; Casse et al., 2000; Heyland, 2000). 
 
Diarrhoea management strategies 
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Diarrhoea management remains inconsistent between ICUs. The management of 
diarrhoea includes diarrhoea management algorithms, rehydration, electrolyte 
replacement, anti diarrhoeal medications, continuation of ETF and the administration of 
metronidazole or glycopeptides for Clostridium difficile (Bowling, 1995). A new 
addition to this debate is probiotics. In non-critically ill situations, probiotics have been 
shown to exert a beneficial effect on the incidence and severity of diarrhoea (Barbut and 
Meynard, 2000; Whelan et al., 2001; Lee and Auyeung, 2003). The place for regular 
probiotic administration in diarrhoea management in critical illness is not yet fully 
explored or understood. 
 
Probiotics 
Probiotics are defined as viable non-pathogenic micro-organisms which when 
ingested, exert a beneficial effect and positive influence on the health and well-being of 
the host (Marteau and Seksik, 2002; Fioramonti et al., 2003). Current evidence
 
suggests 
that probiotic effects are strain specific and the effects seen in one probiotic strain may 
not be seen in a different probiotic strain (Cataldi-Betcher et al., 1983). Furthermore, 
probiotic effects may be enhanced when prebiotic, probiotic or synbiotic preparations 
are administered (defined in Table 1) (Bengmark, 2005; Watkinson et al., 2007; 
Guarner et al., 2008). The most frequently administered probiotics include Lactobacilli, 
Bifidobacilli and Saccharomyces (Thomas et al., 2003; Hammilton-Miller, 2004). 
Probiotics are commercially available in the form of capsules, enriched yoghurts, 
powders and fermented milk and cheese products (Whelan et al., 2001).  
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For reasons of safety and efficacy a probiotic should fulfil strict selection criteria 
(Whelan et al., 2001). A probiotic must have the ability to resist gastric juices and 
exposure to bile, be able to multiply and colonise the digestive tract and maintain safety, 
effectiveness and potency for the duration of its shelf life (FAO/WHO, 2001; 
FAO/WHO, 2002; Senok et al., 2005). 
 
Mechanisms of action of probiotics 
Although the role and beneficial effects of probiotic ingestion remains uncertain, 
recent studies suggest that some probiotics have been used as an adjuvant in the 
treatment and prevention of many diseases including diarrhoea, immuno stimulation, 
urogenital health and cancer prevention (Gorbach, 2000; Klaenhammer, 2000; 
Bengmark, 2002; Thomas et al., 2003; Hammilton-Miller, 2004; Broekaert and Walker, 
2006; Manzoni, 2007). Several probiotic mechanisms of action have been suggested 
including: 1) antagonistic activity; 2) stimulation of mucosal defence; and 3) nutrient 
production in the intestine (Erickson and Hubbard, 2000; Fooks, 2002; Isolauri and 
Salminen, 2004; Sulivan and Nord, 2005). Recent studies suggest that probiotics exert 
their mechanism of action through chemical inhibition and stimulation, nutrient 
competition, immune clearance and competition for adhesion receptors (Bengmark, 
2002). It must be emphasised that the exact mechanisms by which probiotics achieve 
their physiological effect(s) remain unclear (Bengmark, 2002; Baker and day, 2008; 
Quigley, 2008). 
 
The aims of this review 
The aim of this literature review is to identify the role of probiotics in the 
management of enteral tube feeding (ETF) diarrhoea in critically ill, adult patients. 
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Search strategy 
The studies included in this review were identified through the Cochrane 
Library, Pubmed, Science Direct, Medline and the CINAHL databases for English 
language sources published from 1980 to 2010. Key search terms used were: enteral 
nutrition, diarrhoea, critical illness, probiotics, probiotic species and randomised clinical 
control trial. Studies were included if they used a RCT design examining probiotics and 
ETF in critically ill, hospitalised patients experiencing diarrhoea. Combinations of 
critically ill and general ward patient studies were included. Studies were excluded if 
they: (i) did not employ an RCT design; (ii) patients were not hospitalised; and (iii) 
patients were not receiving ETF and probiotics. Reference lists of retrieved papers were 
manually checked and abstracts were reviewed by one reviewer. Papers were selected 
with reference to the aims of this review paper. 
 
Results 
The limited availability of research examining probiotic efficacy in the 
management of ETF diarrhoea in critically ill adult patients was demonstrated with only 
four RCT papers two reporting full studies (Heimburger et al., 1994; Bleichner et al., 
1997), one reporting a pilot RCT (Alberda et al., 2007) and one conference abstract 
reporting an RCT pilot study (Chaboyer et al, 2007) (see Table 2). The design and 
methodologies of these studies are presented in Table 2. 
 
Discussion 
This review has highlighted inconclusive evidence to support probiotic 
administration in critically ill, ETF patients who experience diarrhoea. The larger, multi 
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centre study by Bleichner et al (1997) demonstrated a significant reduction in the 
percentage of diarrhoea days in patients receiving Saccharomyces boulardii 
(S.boulardii) from 18.9% to 14.2%. However, the three smaller studies (Heimburger et 
al., 1994; Alberda et al., 2007; Chaboyer et al., 2007) showed only a trend towards less 
diarrhoea in the probiotic groups.  
 
The absence of a statistically significant difference might be related to a lack of 
power
 
in the studies reviewed. Although statistical significance was not found in the 
smaller studies, a small treatment effect was observed (Heimburger et al., 1994; Alberda 
et al., 2007; Chaboyer et al., 2007). This suggests that probiotics may be beneficial in 
the treatment of ETF diarrhoea; however, larger, adequately powered studies are 
required to support this trend. 
 
There are a number of other identified issues arising from the studies which 
were not reported (Heimburger et al., 1994; Bleichner et al., 1997; Alberda et al., 2007; 
Chaboyer et al., 2007). The infrequent resiting of feeding tubes may directly influence 
bacterial colonisation and potential development of infectious diarrhoea. Although stool 
cultures were reported as a non-significant cause of diarrhoea in two RTCs (Heimburger 
et al., 1994; Bleichner et al., 1997) it was not reported on in the two pilot studies 
(Alberda et al., 2007; Chaboyer et al., 2007).  
 
The ETF preparation and administration techniques, and infection control 
practices were inadequately reported on (Heimburger et al., 1994; Bleichner et al., 1997; 
Alberda et al., 2007; Chaboyer et al., 2007). Only one study reported ETF 
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administration methods. It is known that infection control practices may vary between 
research sites (Alberda et al., 2007). Contamination of ETF is a known cause of 
diarrhoea, particularly in critically ill patients (Marshall and West, 2004. It is possible 
that contamination of ETF formulae may have occurred; however, this was not reported.  
 
Combinations of ICU and ward patients were used by Heimburger et al (1994) 
and Bleichner et al (1997); however,
 
Alberda et al (2007) and Chaboyer et al (2007) 
used ICU patients only (Table 2). Confounding of the treatment effect due to variability 
in patient acuity may limit the generalisation of study findings in critically ill patients. 
 
Patient demographics were not statistically significant between the groups 
(Heimburger et al., 1994; Bleichner et al., 1997; Alberda et al., 2007; Chaboyer et al., 
2007). Severity of illness scores such as APACHE and Sepsis-related Organ Failure 
Assessment scores were inconsistently reported. These recognised and validated scores 
may have provided valuable data to benchmark the severity of critical illness and 
therefore patient acuity. 
 
Severity of illness scores and mortality rates and causes differ between subsets 
of critically ill patients. Probiotics were reported as a non-significant mortality risk 
factor in only one study (Alberda et al., 2007). Mortality was not associated with 
probiotics in the studies reviewed (Heimburger et al., 1994; Bleichner et al., 1997; 
Alberda et al., 2007; Chaboyer et al., 2007). It may be concluded that the scientific 
weaknesses of probiotics such as their mechanisms of action have not been fully 
understood when exploring diarrhoea, ETF, and mortality in critically ill patients. 
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Diarrhoea and Enteral Formulae 
Diarrhoea is frequently defined by the number of loose stools passed each day 
(Pancorbo-Hidalgo et al., 2001; Lebak et al., 2003; Thomas et al., 2003; Whelan et al., 
2003; Elia et al., 2008). Definitions of diarrhoea that rely on a subjective assessment of 
stool consistency and frequency or by the summed daily score of stool frequency, 
consistency and volume unreliably measure diarrhoea in the critical care environment 
(Hart and Dobb, 1988; Duncan et al., 1997; Pancorbo-Hidalgo et al., 2001; Thomas et 
al., 2003; Manley et al., 2007; Elia et al., 2008). Disparity of diarrhoea definitions was 
noted in all studies. Diarrhoea was identified by the duration of diarrhoea monitoring. 
Percentages of diarrhoea days or proportions of diarrhoea free days were inconsistently 
reported (Heimburger et al., 1994; Bleichner et al., 1997; Alberda et al., 2007; Chaboyer 
et al., 2007). The absence of a single agreed diarrhoea definition will continue to 
influence research outcomes and generalisation of study results in the critical care 
environment. 
 
Enteral tube feeding is often cited as a diarrhoea risk factor. Putative factors 
associated with diarrhoea and ETF include fibre enriched ETF, hyper-osmolality and 
contamination of the ETF (Pancorbo-Hidalgo et al., 2001; Whelan et al., 2001; Lebak et 
al., 2003; Whelan et al., 2003; Weisen et al., 2006). Clinical trials examining the effects 
of fibre containing ETF formulae on GIT function show variable results (Thomas et al., 
2003. 
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The various ETF formulae used in the studies reviewed were inconsistently 
reported (Heimburger et al., 1994; Bleichner et al., 1997; Alberda et al., 2007; Chaboyer 
et al., 2007)  (see Table 2). Diarrhoea was found to be inconsistently associated with the 
type of ETF formulae administered. The unpredictability of these results might be 
associated with the ETF formulae, duration of ETF, probiotic species administered, 
inadequately powered sample sizes, or other confounding physiological or 
pharmacological reasons not reported. Interestingly, a trend to continue ETF in the 
presence of diarrhoea was observed in the studies reviewed (Heimburger et al., 1994; 
Bleichner et al., 1997; Alberda et al., 2007; Chaboyer et al., 2007). 
 
 It is important to note that the faecal intestinal flora of study participants was not 
examined for changes to normal GIT microbiota in the four RCTs (Heimburger et al., 
1994; Bleichner et al., 1997; Alberda et al., 2007; Chaboyer et al., 2007). It would be 
beneficial to explore microbial changes at an individual patient level prior to 
administering probiotics. Should alterations to the individual’s intestinal flora occur, 
then it might be appropriate to consider probiotics as an adjuvant to diarrhoea 
management. 
 
Probiotics 
Dissimilarity between probiotic species, dose and frequency of administration 
was evident between the studies (refer to Table 2) (Heimburger et al., 1994; Bleichner et 
al., 1997; Alberda et al., 2007; Chaboyer et al., 2007). Although little is understood 
regarding the therapeutic dose(s) of probiotic species, a minimum of 5 x 10
6
 colony 
forming units (cfu) is suggested to guide the clinical benefits in most diarrhoeal and 
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disease states (Sartor, 2004). The disparity between probiotic species and concentrations 
of the studies reviewed (100,000 000
7
, 500mg
8
, 9 x 10
11
 bacteria
9
, 450 billion
10
 cfu) 
may attribute to the inconclusive findings. 
 
The principle of using harmless bacteria to overcome pathological intestinal 
pathogens has been acknowledged for many years (Montrose and Floch, 2005. Probiotic 
ingestion by definition infers that the host will receive a physiological and therapeutic 
benefit (Isolauri and Salminen, 2004; Chaboyer et al., 2007). The risk of morbidity must 
be balanced against the sparse evidence supporting probiotic efficacy in the 
management of ETF related diarrhoea in critically ill patients. 
 
S.boulardii is a yeast used to treat antibiotic and ETF diarrhoea in critically ill 
adults at a dose of 1-2 g/day. Seven cases of fungaemia were observed in critically ill, 
mechanically ventilated patients who were treated with broad spectrum antibiotics and 
had central venous catheter access between June 1996 and October 1998 (Lherm et al., 
2002). Six of these patients were treated with S.boulardii. Complications associated 
with fungaemia in critically ill and immunocompromised patients have been 
increasingly reported since the 1990s. Lherm et al (2002) argue that S.boulardii should 
not be administered to critically ill or immunocompromised patients. Surprisingly, the 
largest study by Bleichner et al (1997) did not report any cases of fungaemia in the 
S.boulardii treated group. 
 
Most research to date has focused on the mechanisms by which pathogenic 
bacteria exert their effect (Rolfe, 2000; Fioramonti et al., 2003; Fedorak and Madsen, 
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2004). A better understanding of probiotics mechanism of action will result in more 
efficacious application to the symbiotic relationship between the host and gut barrier 
function.  
 
The scientific weaknesses of probiotics have been inadequately examined and 
cautious use is recommended in critically ill patients. Commonly noted scientific 
weaknesses of probiotics which may explain the absence of a significant reduction in 
diarrhoea includes: 
 Numerous and often inadequately described probiotic genera, species and strains 
with varying effects at varying endpoints in the GIT; 
 Inadequate understanding of probiotic species and strain dosages and the 
efficacious window of opportunity of administration; and 
 Inconsistent or inadequately stored probiotic cultures may result in reduced 
bacterial viability (Guarner et al., 2008). 
 
Why might probiotics be harmful? 
 Alterations to intestinal micro flora during critical illness lend the intestine 
vulnerable to pathogenic microorganisms. Factors influencing this pathogenic 
environment include gut dysmotility, changes in nutrient availability, pH balance, 
oxygen supply/demand, increased release of stress hormones such as catecholamine, 
osmolality of ETF, medications, and antibiotics (Singhi and Baranwal, 2008). 
 
Theoretically, probiotics are responsible for four types of side effects including 
1) systemic infections; 2) injurious metabolic activities; 3) undue or excessive immune 
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stimulation; and 4) gene transfer (Hammilton-Miller, 2004; Yan and Polk, 2006; Elia et 
al., 2008). 
 
Several studies did not meet the inclusion criteria of this review paper as 
diarrhoea was not identified as an outcome measure (Rayes et al., 2002; Falcao et al., 
2004; Kotzampassi et al., 2006; Spindler-Vesel et al., 2007; Besselink et al, 2008; 
Forestier et al., 2008) (see Table 3). However, it is important to discuss the efficacy of 
probiotics in relation to critical illness. A number of clinical trials have reported 
significant reduction in infection acquisition rates, systemic inflammatory response, 
sepsis, ICU and hospital lengths of stay, early return of bowel function, reduced 
mechanical ventilation days, decreased intestinal permeability and mortality rates in the 
probiotic groups (Rayes et al., 2002; Kotzampassi et al., 2006; Alberda et al., 2007; 
Spindler-Vesel et al., 2007; Forestier et al., 2008; Klarin et al., 2008). Conversely, some 
studies found no increase in infection acquisition rates or mortality (Besselink et al., 
2008) in the probiotic treated patients. These findings may be because of the small 
sample sizes, incongruence’s between severity of illness scores, heterogeneity of 
participant populations, variations between probiotic/synbiotic species and doses, and 
inadequate pre-trial testing of probiotic combinations. 
 
Mortality and probiotic trials have been infrequently reported on for reasons 
including inadequate sample sizes and mortality not cited as a study endpoint. Besselink 
et al (2008) demonstrated a significant mortality rate which is in contrast to many other 
study findings (Heimburger et al., 1994; Bleichner et al., 1997; Falcao et al., 2004; 
Kotzampassi et al., 2006; Alberda et al., 2007; Chaboyer et al., 2007). 
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In the Besselink et al (2008)
 
study, a six species, powdered probiotic preparation 
was administered enterally or orally, twice daily for twenty-eight days. Baseline group 
characteristics were similar. Infectious complications occurred in 30% (n=46) of the 
probiotics and 28% (n=41) of the placebo patients. Probiotic group mortality was 16% 
(n=24) compared to placebo group mortality of 6% (n=9). Bowel ischaemia was 
diagnosed at autopsy in nine probiotic group patients (eight fatal) and no placebo group 
patients (p=0.004). 
 
Of particular note in the Besselink et al (2008) study was the significant bowel 
ischaemia and mortality findings in the probiotic group. These findings may be 
potentially related to the following study limitations: 
 
 Organ failure rates were significantly higher in the probiotic (n=20) versus the 
placebo (n=7) group (p<0.02) on the day of randomisation; 
 There was inadequate pre-trial testing of the combined probiotic preparation; 
 Higher probiotic bacterial loads may have increased oxygen demand resulting in 
cumulative gut ischaemia; 
 Injection of probiotics directly into the jejunum bypassing the acid environment 
of the stomach might have led to an increased bacterial concentration in the 
small bowel; 
 The ETF formulae combined with probiotic bacteria and fibre might have 
resulted in an accelerated fermentation process; 
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 Delayed upper GIT peristalsis seen in pancreatitis may have increased exposure 
to the probiotic; 
  Many patients had previous exposure to alcohol misuse, were potentially 
immunocompromised and then exposed to a bacterial, probiotic load. These 
combined factors may have exacerbated intestinal permeability often seen in 
pancreatitis patients (Marteau, 2008; Bjarnason et al., 2008; Reddy and MacFie, 
2008; Reid et al., 2008). 
 
The study by Besselink et al (2008) raises many questions. Does probiotic 
therapy require additional oxygen requirements that cannot be met in a critically ill 
patient with reduced splanchnic blood flow? Is it possible that multiple organ failure 
associated with sepsis or infection affects the intestine’s 1) epithelial lining; 2) 
homeostatic environment; 3) regulation of microbial environment; and 4) modifies 
commensal bacteria? Does the site of probiotic administration such as intra gastric or 
jejunal, affect splanchnic oxygen consumption and GIT permeability in critical illness? 
Are the results of Besselink et al (2008) study only evident in acute pancreatitis patients 
who are at an increased risk of intestinal permeability or are these results similar in 
other subsets of critically ill patients? The answers to these physiological questions 
require further research. 
 
A recent systematic review (Whelan and Myers, 2010) identified 72 articles 
examining probiotic safety in enterally tube fed patients. Of these articles, 20 were case 
reports of adverse events in 32 patients and 52 were articles that reported 53 trials in 
which 4131 patients received probiotics. Notably, the majority of trials reported either 
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no effect of a positive effect related to the outcome measure of safety (mortality and 
infection). An increase in patient complications was reported in only three trials. These 
complications were predominantly non-infectious and in specific cohorts of patients 
including transplant and pancreatitis patients. Probiotics were administered via a post-
pyloric tube in two of these three trials. Whelan and Meyers (2010) recommend that 1) 
safety trials be conducted when a probiotic or combination of probiotics is administered 
in a disease state for the first time; 2) efficacy trials should include a data monitoring 
committee to monitor adverse events; 3) probiotics associated with an increased risk of 
adverse events in specific disease states should not be administered to those particular 
patients; and 4) administer probiotics cautiously in high risk patients such as critically 
ill patients and patients with a central venous line insitu. A notable recommendation by 
Whelan and Meyers (2010) is that probiotics should not be with held in high risk 
patients or research as the potential benefits outweigh the potential risks. In this 
situation, a risk-benefit analysis and surveillance monitoring is required for individual 
patients to detect early adverse events. 
 
Recommendations 
This literature review has identified a number of areas that require further 
attention. The definition and efficacy of probiotics in severely and critically ill patients 
requires cautious application. Clearly, probiotics are not beneficial to the host when 
mortality is observed in severely ill pancreatitis patients. Mechanisms of actions of 
probiotics may be linearly affected by the probiotic species, dose, frequency and method 
of administration in specific disease states such as diarrhoea, constipation and 
infections. Future research must examine morbidity and mortality causes in critically ill 
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patients who receive probiotics. Intestinal flora changes must be examined at an 
individual patient level prior to the addition of probiotics as adjuvant treatment in 
critical illness. 
 
Conclusion 
From the evidence reviewed, it would appear that probiotics do not conclusively 
reduce the incidence of ETF related diarrhoea in critically ill patients. An increased 
incidence of mortality in probiotic patients, on the basis of one study must lend caution 
to their use in critically ill patients. Further in-vivo and animal studies are required to 
confirm the mortality findings in severely and critically ill patients. Only then, can 
probiotics be safely administered to critically ill patients to manage enteral tube feeding 
diarrhoea. In conclusion, as clinicians, we need to challenge the theoretical approach 
that probiotics are beneficial to the critically ill patient? 
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Table 1 Definitions
 
Prebiotic Non-digestible substances that beneficially effect the host 
through selectively stimulating the growth and/or activity of 
indigenous bacteria. 
Probiotic Viable, non-pathogenic micro-organisms which when 
ingested exert a beneficial effect and positive influence on 
the health and well-being of the host. 
Synbiotic Products combining both probiotic and probiotic. Synbiotics 
provide a beneficial synergistic effect to the host. 
(Cataldi-Betcher et al., 1983;Marteau and Seksik, 2002; Fioramonti et al., 2003) 
 
Table 2 Probiotic and Diarrhoea Studies published between 1980 and 2008 
Author Methodology Setting 
Participants 
Aim Intervention Results 
Heimburger et al 
(1994) 
Prospective, 
randomised, 
double-blind, 
placebo 
controlled trial 
Multi centre: 
ICUs and general 
wards teaching 
and general 
hospitals between 
September 1988 
and February 
1991. 
 
Participants: 
ETF critically ill 
adult patients 
Assess whether 1) 
antibiotics, 
hypoalbuminaemia or 
hypertonic ETF is 
associated with 
diarrhoea; 2) 
determine the 
frequency of ETF 
related diarrhoea; 3) 
does Lactobacillus 
reduce the incidence 
of ETF diarrhoea 
L acidophilus &  
L. bulgaricus 
1g (n=18) vs placebo 
(n=23) TDS. Study 
duration not identified 
 
ETF: Osmolite HN, Isocal 
or Sustacal to maximum 10 
days 
 
ICU patients (N=25): 
Probiotic group (n=13) vs 
placebo group (n=12) 
 
Randomisation: 
Stratified random 
assignment with regard to 
3 putative risk factors: 
1. Antibiotics; 
2. Serum albumin ≤25 or 
≥25 g/L; 
3. ETF osmolality ≤ 350 or 
≥350 mosmol/kg 
 
 3 diarrhoea risk factors: 
1. Antibiotics 
2. Hypoalbuminaemia 
3. ETF osmolality 
 
 Diarrhoea defined as 
the excretion of >200g 
of stool in 24 hours; 
 34 patients completed 
5 days of ETF without 
diarrhoea 
 Diarrhoea developed in 
17% (n=7) of patients 
 Lactobacillus did not 
alter risk of diarrhoea 
 No statistical 
significance identified 
in the incidence of 
diarrhoea between the 
2 groups 
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Bleichner et al 
(1997)
 
 
 
 
 
 
 
 
Prospective, 
randomised, 
double-blind, 
placebo 
controlled trial 
 
Multi centre (11) 
ICUs in teaching 
and general 
hospitals between 
April 1992 and 
June 1993 
 
Participants: 
Adult ICU 
patients expecting 
ETF > 6 days 
 
Assess prophylactic 
effect of S.boulardii 
on diarrhoea in ETF 
critically ill patients 
 
 
 
 
 
 
S.boulardii 
500mg (n=64) vs placebo 
(n=64) QID for 21 days or 
withdrawal of ETF 
 
ETF: Intact protein diet 
without fibre of lactose for 
minimum 6 days 
 
Randomisation: 
Stratified blocks of 4 
random assignment with 
regard to hospital 
 
 15 risk factors studied 
 5 independent risk 
factors:  
1. Previous TPN; 
2. Malnutrition; 
3. Hypoalbuminaemia <26 
g/l; 
4. Infection site;  
5. Hyper/hypothermia 
 
 Diarrhoea measured 
as number of days a 
patient experienced 
diarrhoea and 
volume and 
consistency of stool 
 Frequency of 
diarrhoea days 
18.9% (placebo) vs 
14.2% (S.boulardii) 
(p=0.0069) 
 Diarrhoea days 
reduced by 25% 
 Risk factor 
adjustment showed 
diarrhoea days 
reduced 42% vs 25% 
= 52% reduction 
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Alberda et al 
(2007) 
Double-blind, 
placebo 
controlled pilot 
RCT; 
Single centre 
ICU 
 
Participants: 
ETF critically 
ill adult pts 
Do viable and non-
viable probiotics 
modulate intestinal 
permeability and 
immune function and 
prevent MODS onset 
in critically ill 
patients; 
 
Do bacterial sonicates 
with bacterial DNA 
have similar effects as 
viable bacteria 
Ix: ProbioticsVSL#3 BD 
for 7 days. Each sachet = 9 
10
11
 bacteria viable 
probiotic n=10; sonicate 
(n=9);  
Control: placebo (n=9) 
 
ETF: Jevity plus within 48 
hrs for all groups 
 
Randomisation: 
Random assignment, 
method of assignment not 
discussed 
 Higher incidence of 
diarrhoea in placebo 
vs probiotic and 
sonicate groups (23% 
vs 14% vs 12%). Not 
statistically 
significant; 
 Improved immune 
activity, decreased 
intestinal permeability 
& MODS in probiotic 
group 
Chaboyer et al 
(2007) 
Prospective, 
randomised, 
double-blind, 
placebo 
controlled trial 
Single centre 
ICU 
 
Participants: 
Adult, ICU 
patients 
Evaluate the efficacy 
of probiotics to reduce 
diarrhoea in ETF 
critically ill patients 
VSL#3 (n=25) BD vs 
placebo (n=20) BD 
 
ETF: Not reported 
 
Randomisation: 
Method not identified 
 
 Diarrhoea measured 
using validated 
King’s College Stool 
Chart 
 Study duration 8.5 to 
12.4 days 
 Risk factors adjusted 
for include: 
1. Albumin; 
2. Duration of EN 
 Liquid stool volume 
reduced by 50% in 
the VSL#3 treated 
group (p=0.05) 
 No adverse events 
were observed 
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Table 3 Probiotics in Critical Illness 
Author Methodology Setting 
Participants 
Aim Intervention Results/Limitations 
Rayes et al 
(2002) 
Prospective, 
randomized, 
double-blinded, 
placebo-
controlled trial 
Single centre ICU 
 
Participants: 
Adult patients 
undergoing liver 
transplantation 
To examine three 
different treatment 
strategies on the 
incidence of early post 
operative infection 
following liver 
transplantation. 
 
Group 1: early enteral 
nutrition (fibre-free) 
with selective bowel 
decontamination 
(SBD); 
 
Group 2: fibre-
enriched formula plus 
live Lactobacillus 
plantarum 299 (L. 
plantarum); 
 
Group 3: heat 
inactivated (placebo) 
L. plantarum 299. 
 EEN started within 
24 hr of operation 
and continued until 
day 12 post 
operatively 
 
Group1: SBD of 80 mg 
Tobramycin, 500 mg 
Amphotericin B, 100 
mg colistin sulphate 
QID for 6 weeks post 
operatively (n=32); 
 
Group 2: Nutrison 
Fibre plus L. planatrum 
10
9
 cfu BD for 12 post 
operative days (n=31); 
 
Group 3: heat-killed L. 
planatrum plus oat 
fibre BD for 12 post 
operative days (n=32) 
 
Randomisation: 
Stratified 
randomisation by 
sealed envelope 
 Serum albumin higher, 
shorter ICU and 
hospital LOS and 
earlier return of bowel 
function (not 
significant) in group 2; 
 Significantly less 
infections in group 2 
(p=0.017); 
 
Limitations: 
 Statistical significance 
poorly identified and 
discussed; 
 Small sample size; 
 Extrapolation of results 
to include probiotic 
administration to the 
donor is 
unsubstantiated 
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Falcao et al 
(2004) 
Prospective 
RCT 
Blinding of 
participants not 
identified 
Single centre ICU 
 
Participants: 
ETF brain injured CI 
pts 
 
Age 16 – 50 
Evaluate the effects of 
EEN with glutamine 
against infectious 
complications, LOS 
ICU, time spent 
mechanical ventilation 
Intervention: 
Glutamine 30g 
(administered as a 
bolus), 240 ml 
fermented milk with 
probiotic Lactobacillus 
johnsonii (La 1) 
(n=11); 
Control: Standard 
polymeric diet (n=12) 
 
Randomisation: 
Method not identified 
 No mortality 
observed; 
 Higher infection rate 
in control group 
(p=0.03); 
 Infections per patient 
higher (p<0.01), ICU 
LOS (p<0.01) and 
days mechanically 
ventilated (p=0.04) 
higher in control 
group 
 
Limitations: 
 ICU LOS included 
ICU and ward days; 
 Small sample size;  
 Low statistical power 
of 80% sought 
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Kotzampassi et 
al (2006) 
Prospective, 
randomized, 
double-blind, 
placebo-
controlled, pilot 
trial 
 
This study is an 
interim analysis 
at 60% 
recruitment into 
the RCT 
Multi centre (5) ICU  
 
Participants: 
Mechanically 
ventilated, severe 
poly trauma, adult 
ICU patients with 
expected ICU LOS 
>15 days 
To examine the 
benefits (infection 
rates, duration of 
mechanical 
ventilation, mortality) 
of combination 
treatment (synbiotics) 
with pre- and 
probiotics in critically 
ill, long term 
ventilated patients. 
Intervention: synbiotic 
formulae consisted of 
1) four probiotics (10
11
 
cfu each) Pediococcus 
pentosaceus, 
Leuconostoc 
mesenteroides, 
Lactobacillus 
plantarum, 
Lactobacillus ssp 
paracasei; and 2) 
prebiotics of insulin, 
oat bran, pectin, 
resistant starch. Dose 
of 12g daily for 15 days 
(n=35); 
Control: placebo 
(n=30) 
 
Randomisation: 
Random assignment 
 Synbiotic treated 
patients developed less 
infection (p=0.01), 
SIRS/sepsis (p=0.02), 
mortality, and reduced 
days under mechanical 
ventilation (p=0.001); 
 Trend toward 
normalization of upper 
GIT motility in 
synbiotic group 
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Spindler-
Vesel et al 
(2007) 
Prospective, 
randomized, 
controlled trial. 
 
Participant 
blinding to 
study 
investigators 
not identified. 
Single centre ICU 
 
Participants: 
Multiple trauma, 
adult, patients 
To examine the 
relationship and 
extent of synbiotics, 
prebiotics, glutamine, 
peptide on 1) 
intestinal 
permeability (IP); 
and 2) infection rate, 
mortality, ICU LOS, 
days of mechanical 
ventilation and 
incidence of MOF 
Group 1: Alitraq EN plus 
1.55 g glutamine, 446 mg 
arginine, 154 mg α-
linoleic acid per 100 ml; 
Group 2: Nova Source 
EN; 
Group 3: Nutricomp 
peptide EN; 
Group D; Nutricomp 
standard plus synbiotic 
(Pediococcus 
pentocsaceus 10
10
, 
Lactococcus raffinolactis 
10
10
, L. paracacsei sub 
species paracasei 10
10
, L. 
plantarum 10
10
, and 4 
fibres (β glucan, insulin, 
pectin, resistant starch) 
 En started within 24 hrs 
of ICU admission 
 EN stopped x 6 hr over 
night; 
 Total patient sample: 
N=113 
 
Randomisation: 
Random allocation 
 Significant less 
combinations of 
infections in Group D 
(p=0.003); 
 Intestinal permeability 
decreased only in 
Group D from 0.148 
(0.056-0.240) on day 4 
to 0.061 (0.040-0.099) 
on day 7 (p < 0.05); 
 Total gastric retention 
volume higher in 
Group D (p <0.02) 
 
Limitations: 
Patient numbers per 
group not identified 
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Forestier et al 
(2008) 
Prospective, 
randomised, 
double-blind, 
placebo 
controlled pilot 
RCT 
Single centre ICU 
 
Participants: 
ICU patients with 
LOS > 48 hrs and 
NGT 
Investigate the 
effectiveness of an 
oral probiotic on 
gastric and 
respiratory 
colonization/infection 
with Pseuomonas 
aeruginosa (P. 
aeruginosa) 
Intervention: Lactobacillus 
casei rhamnosus 10
9
 cfu 
BD from day 3 of ICU 
admission to discharge 
(n=102); 
 
Control: placebo (not 
identified) BD from day 3 
ICU admission to 
discharge (n=106) 
 
Randomisation: 
Computer generated, 
equal random allocation 
through sealed envelopes 
 
 
 Delayed (11 vs 50 
days) respiratory 
colonization of P. 
aeruginosa (p=0.01) 
in probiotic group; 
 Reduced P. 
aeruginosa VAP in 
probiotic group (not 
significant) 
 
Klarin et al 
(2008) 
Prospective, 
randomized, 
double-blind, 
placebo 
controlled RCT 
Single centre ICU 
 
Participants: 
ICU patients with 
LOS > 3 days, >18 
years of age, no 
previous positive C. 
difficile infection, 
commence ETF 
within 24 hours of 
ICU admission, no 
allergy to study 
protocol probiotics, 
not moribund 
Investigate the 
effectiveness of 
enteral administration 
of Lactobacillus 
plantarum 299v on 
the prevalence of 
Clostridium difficile 
(C. difficile) infection 
in critically ill 
patients treated with 
antibiotics 
Intervention: fermented 
oatmeal gruel with 8 x 10
8
 
cfu/mL of Lactobacillus 
plantarum 299v 100 ml 
bolus doses BD by 6 days, 
followed by 50 ml bolus 
doses BD ICU discharge.  
 
Control: Same gruel as the 
intervention group, less 
the Lactobacillus 
plantarum 299v. Lactic 
acid added to achieve 
same pH. 
 
Randomisation: 
Method not identified 
 No C. difficile 
colonisation in 
intervention group; 
 C. difficile in 19% of 
control group 
 No differences in 
frequency or 
consistency of bowel 
movements. Statistics 
not reported. 
 38 
 
Besselink et al 
(2008) 
Prospective, 
randomized, 
double-blinded, 
placebo-
controlled trial 
Multi ICU centre  
 
Participants: 
First episode of 
severe, acute, 
pancreatitis in adult 
patients 
Assess the effects of 
probiotic prophylaxis 
on infectious 
complications in 
patients with severe, 
acute pancreatitis 
Intervention: 6 strains of 
freeze-dried viable 
bacteria: L. acidophilus, L. 
casei, L, salivarius, 
Lactococcus lactis, 
Bifidobacterium bifidum, 
Bifidobacterium lactis to 
total of 10
10
 bacteria plus 
cornstarch and 
maltodextrins (n=152); 
 
Placebo: cornstarch and 
maltodextrins only 
(n=144) 
 
Probiotic or placebo 
administered BD and 
added to continuously 
infused fibre-enriched 
ETF (Nutrison Multi 
Fibre) or until oral intake 
resumed for 28 days. 
 
Randomisation: 
Computer generated 
permuted blocks of 4, 
balanced by admitting 
hospital and presumed 
cause of pancreatitis 
 
 Significantly higher 
mortality in probiotic 
group (p=0.01); 
 Bowel ischaemia 
higher in probiotic 
group 9 vs 0; 
p=0.004); 
 Early onset MOF in all 
probiotic patients who 
died 
 
Limitations: 
 Inadequate pre-trial 
testing of probiotic 
combination 
(Ecological 641); 
 MOF rate on day of 
randomisation was 
significantly higher 
(p<0.02) in the 
probiotic (n=20) vs 
placebo (n=7) groups; 
 Pre-treatment MOF 
events closely 
correlate mortality 
rates (24 vs 9) and 
incidence of bowel 
ischaemia (9 vs 0); 
 Haemodynamic 
instability is a pre-
cursor to MOF and 
non-occlusive bowel 
ischaemia in acute 
pancreatitis; 
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 Hyper caloric ETF 
and inadequate gut 
function may explain 
bowel ischaemia; 
 High doses of 
probiotics (5 x 10
9
 cfu 
BD) untested; 
 Probiotic bypassing of 
gastric acid may have 
led to higher bacterial 
colonization in the 
jejunum; 
 Infectious 
complications (the aim 
of this study) poorly 
discussed 
 
 
